Biotech Values

[DewDiligence]

XERS +28%/AH on FDA approval of Recorlev for Cushing’s syndrome:

https://finance.yahoo.com/news/xeris-biopharma-announces-u-fda-213000491.html

Xeris Biopharma Holdings…today announced the U.S. Food and Drug Administration (FDA) approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.